Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia - A Randomized, Double-Blind, Placebo-Controlled, Phase III Study -
Open Access
- 1 June 2020
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 84 (6), 994-+
- https://doi.org/10.1253/circj.CJ-19-0358
Abstract
Background: This study is the first to evaluate the short-term efficacy and long-term safety of AZD0585, a mixture of omega-3 free fatty acids, in Japanese patients with dyslipidemia. Methods and Results: In this randomized double-blind placebo-controlled Phase III study, 383 patients were randomized to 2 g AZD0585, 4 g AZD0585, or placebo once daily for 52 weeks. Eligible patients had low-density lipoprotein cholesterol (LDL-C) levels controlled regardless of statin use, and triglyceride levels between 150 and 499 mg/dL. The least-squares (LS) mean percentage changes in triglyceride concentrations from baseline to the 12-week endpoint (mean of measurements at Weeks 10 and 12) in the 2 and 4 g AZD0585 and placebo groups were -15.57%, -21.75%, and 11.15% respectively (P<0.0001 for both AZD0585 doses vs. placebo). No clinically significant changes from baseline to the 12-week endpoint in total cholesterol, LDL-C, and LDL-C/apolipoprotein (Apo) B were found with AZD0585. High-density lipoprotein cholesterol (HDL-C) was slightly increased and very low-density lipoprotein cholesterol, non-HDL-C, ApoC-II, and ApoC-III were decreased with AZD0585 compared with placebo at the 12-week endpoint. Lipid profiles up to Week 52 were consistent with those up to the 12-week endpoint. No clinically important safety concerns were raised. Conclusions: AZD0585 significantly decreased serum triglyceride levels compared with placebo at the 12-week endpoint and was generally safe and well tolerated in Japanese patients with dyslipidemia.This publication has 26 references indexed in Scilit:
- The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemiaLipids in Health and Disease, 2016
- Hypertriglyceridemia and Cardiovascular Diseases: RevisitedKorean Circulation Journal, 2016
- Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trialJournal of Clinical Lipidology, 2014
- Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of AtherosclerosisJournal of Atherosclerosis and Thrombosis, 2013
- Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan ^|^mdash;2012 VersionJournal of Atherosclerosis and Thrombosis, 2013
- Values of Cardio-Ankle Vascular Index (CAVI) between Amami Islands and Kagoshima Mainland Among Health Checkup ExamineesJournal of Atherosclerosis and Thrombosis, 2012
- Management of Type IIb DyslipidemiaJournal of Atherosclerosis and Thrombosis, 2012
- Safety Considerations with Fibrate TherapyThe American Journal of Cardiology, 2007
- Safety Considerations with Niacin TherapyThe American Journal of Cardiology, 2007
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001